<DOC>
	<DOC>NCT02960204</DOC>
	<brief_summary>This is a multicenter, randomized, double-blind, placebo-controlled trial involving subjects with NASH cirrhosis and severe portal hypertension (defined as HVPG ≥12 mmHg as determined by the central reader assigned to this study). Upon successful screening, subjects will be randomized to receive either emricasan 50 mg BID, 25 mg BID, or 5 mg BID or matching placebo BID.</brief_summary>
	<brief_title>Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Hypertension, Portal</mesh_term>
	<mesh_term>Caspase Inhibitors</mesh_term>
	<criteria>Male or female subjects 18 years or older, able to provide written informed consent and able to understand and willing to comply with the requirements of the study. Cirrhosis due to NASH with exclusion of other causes of cirrhosis (e.g. chronic viral hepatitis, alcoholic liver disease, etc.) Compensated cirrhosis OR Decompensated cirrhosis with no more than 1 prior significant decompensating event Severe portal hypertension defined as HVPG ≥12 mmHg Subjects who are on NSBB, nitrates, diuretics, lactulose, rifaximin, or statins must be on a stable dose for at least 3 months prior to Day 1 Willingness to utilize effective contraception (for both males and females of childbearing potential) from Screening to 4 weeks after the last dose of study drug Evidence of severe decompensation Severe hepatic impairment defined as a ChildPugh score ≥10 ALT or AST &gt;5 times upper limit of normal (ULN) during screening Estimated creatinine clearance &lt;30 mL/min Prior transjugular intrahepatic portosystemic shunt or other portosystemic bypass procedure Known portal vein thrombosis Symptoms of biliary colic, e.g. due to symptomatic gallstones, within the last 6 months, unless resolved following cholecystectomy Current use of medications that are considered inhibitors of OATP1B1 and OATP1B3 transporters Alphafetoprotein &gt;200 ng/mL History or presence of clinically concerning cardiac arrhythmias, or prolongation of screening (pretreatment) QTcF interval of &gt;500 msec History of or active malignancies, other than those successfully treated with curative intent and believed to be cured Significant systemic or major illness other than liver disease Use of controlled substances (including inhaled or injected drugs) or nonprescribed use of prescription drugs within 1 year of screening If female: planned or known pregnancy, positive urine or serum pregnancy test, or lactating/breastfeeding Previous treatment with emricasan or active investigational medication (except methacetin) in a clinical trial within 3 months prior to Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>cirrhosis</keyword>
	<keyword>Portal Hypertension</keyword>
	<keyword>Non-alcoholic Steatohepatitis</keyword>
	<keyword>Liver cirrhosis</keyword>
</DOC>